Seres Therapeutics amends bylaws to adopt universal proxy rules and update nomination procedures

Seres Therapeutics, Inc.

Amended bylaws require compliance with SEC Rule 14a-19 for non-Board director nominee solicitations.
Enhanced disclosure for stockholder nominations includes derivative interests and relationships with the Company.
Stockholders may nominate no more director candidates than open board seats.
Proxies solicited by stockholders must use a proxy card color other than white.
Added personal jurisdiction and service-of-process clarifications for foreign actions under forum selection clause.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Seres Therapeutics, Inc.: Adopted Amended and Restated Bylaws with changes to proxy rules, stockholder nominations, and technical updates (effective 2024-01-02).

Change: bylaw amendment
Effective: 2024-01-02

Exact text from the filing

On January 2, 2024, the Board of Directors (the “ Board ”) of Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”), which became effective the same day.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-000683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.